Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026
Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026
Company

BeiGene Ltd to Become BeOne Medicines Ltd, Emphasizing Global Oncology Commitment

Fineline Cube Nov 15, 2024

China-based biotechnology company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a proposed...

Company Deals

Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China

Fineline Cube Nov 15, 2024

Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its...

Policy / Regulatory

NMPA Issues Interim Provisions for Overseas MAHs’ Designated Domestic Responsible Persons

Fineline Cube Nov 15, 2024

The National Medical Products Administration (NMPA) has released the “Interim Provisions on the Management of...

Company Drug

Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study

Fineline Cube Nov 15, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based pharmaceutical company, has announced that it has...

Company Deals

PegBio Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 15, 2024

PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...

Company Drug

Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials

Fineline Cube Nov 15, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Drug

WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line

Fineline Cube Nov 15, 2024

China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans...

Company Drug

Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance

Fineline Cube Nov 15, 2024

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...

Company Drug

Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC

Fineline Cube Nov 15, 2024

Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval...

Company

BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care

Fineline Cube Nov 15, 2024

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments,...

Company Drug

Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study

Fineline Cube Nov 14, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...

Company Medical Device

GE Healthcare’s SIGNA MAGNUS MRI Scanner Receives FDA 510(k) Clearance

Fineline Cube Nov 14, 2024

US medical device and life sciences leader GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals

Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company

Fineline Cube Nov 14, 2024

Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...

Company Drug

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer

Fineline Cube Nov 14, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...

Company Drug

Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China

Fineline Cube Nov 14, 2024

China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with...

Company Deals

Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund

Fineline Cube Nov 14, 2024

Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...

Company Drug

Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment

Fineline Cube Nov 14, 2024

The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC

Fineline Cube Nov 14, 2024

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...

Company Deals

Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research

Fineline Cube Nov 14, 2024

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...

Company Deals

BioNTech Seals Acquisition of China’s Biotheus for Up to $950M

Fineline Cube Nov 14, 2024

China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...

Posts pagination

1 … 216 217 218 … 615

Recent updates

  • Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
  • J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
  • Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
  • FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.